Although accumulating evidence highlights FGF21’s immense therapeutic potential for metabolic disorders such as obesity, insulin resistance, and type 2 diabetes, key gaps persist in our understanding of its systemic actions. Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.